MS4A1 Recombinant Monoclonal Antibody
Description
CUSABIO conducted a meticulous production process to generate the MS4A1 recombinant monoclonal antibody. First, B cells were isolated from the spleen of an immunized animal, using recombinant human MS4A1 protein as the immunogen. Following that, RNA was extracted from the B cells and converted into cDNA through reverse transcription. Using the cDNA as a template, the gene encoding the MS4A1 antibody was amplified with a degenerate primer and inserted into a vector. The recombinant vector was then transfected into host cells to facilitate efficient antibody expression. The MS4A1 recombinant monoclonal antibodies were harvested from the cell culture supernatant and purified using affinity chromatography. This antibody shows reactivity with human and dog MS4A1 protein in ELISA.
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
CUSABIO has meticulously developed the MS4A1 recombinant monoclonal antibody through a rigorous production process. The process begins with isolating B cells from the spleen of an immunized animal, using recombinant human MS4A1 protein as the immunogen. RNA is then extracted from these B cells and converted into cDNA via reverse transcription. Utilizing this cDNA as a template, the gene encoding the MS4A1 antibody is amplified using degenerate primers and subsequently inserted into a vector. This recombinant vector is then transfected into host cells to facilitate efficient antibody expression. The MS4A1 recombinant monoclonal antibodies are harvested from the cell culture supernatant and purified using affinity chromatography. This antibody demonstrates reactivity with both human and dog MS4A1 protein in ELISA assays.
Target Background
MS4A1 is a B-lymphocyte-specific membrane protein that plays a crucial role in regulating cellular calcium influx. This influx is essential for the development, differentiation, and activation of B-lymphocytes. MS4A1 functions as a component of the store-operated calcium (SOC) channel, promoting calcium influx upon activation by the B-cell receptor/BCR.
- Our research revealed that a small subset of papillary thyroid carcinomas (less than 10%, primarily of the classic variant) exhibited aberrant membranous expression of CD20. PMID: 29079175
- Our findings support the inclusion of CD200 in routine Chronic lymphoproliferative disorders panels as it is valuable for subcategorization. However, including CD20 ABC in routine panels is not recommended but might be considered for challenging diagnostic cases or when anti-CD20 therapy is planned. PMID: 29567884
- This study demonstrated that 3' UTR NOTCH1 mutations are associated with low CD20 expression and relative resistance to anti-CD20 immunotherapy in vitro. PMID: 28550186
- Our findings suggest that the relationship between complement-regulatory proteins CFHR1 and CFHR3 and response to anti-CD20 mAb therapy varies based on the specific anti-CD20 mAb used. PMID: 27528699
- Limiting the antibody-induced induction of immunosuppressive reactive oxygen species may enhance the anti-leukemic efficacy of anti-CD20 therapy in chronic lymphocytic leukemia. PMID: 27097113
- Case Report: primary cutaneous T-cell lymphoma with aberrant CD20 expression. PMID: 27840885
- Data indicate that insulitis (destruction of pancreatic beta-cells and their ability to produce/secrete insulin) occurs in two distinct profiles in type 1 diabetes. These profiles differ in the proportion of CD20-positive B-lymphocytes (relative to CD4-positive T-lymphocytes) present within the infiltrate. Increased infiltration of CD20-positive B-lymphocytes leads to more aggressive disease progression. PMID: 26858360
- PZ-DHA also arrested MDA-MB-231 cell division at the G2/M phase and down-regulated expression of cyclin B1 and cyclin-dependent kinase 1 (CDK1). PMID: 27535497
- There is a high CD23a/CD23b ratio of chronic lymphocytic leukemia cells, demonstrating that in a subset of CLL cases, low CD23 expression along with high CD20 and CD38 expressions may serve as a surrogate for trisomy 12. PMID: 26119874
- IL-17-producing pathogenic T lymphocytes co-express CD20 in primary Sjogren's syndrome patients. PMID: 26814615
- Studies indicate that CD20 antigen expression is absent in various diffuse large B cell lymphomas (DLBCLs), including plasmablastic lymphoma, primary effusion lymphoma, anaplastic lymphoma, kinase-positive DLBCL, and large B cell lymphoma arising in human herpesvirus 8-associated multicentric Castleman disease. PMID: 26459310
- Lipid formulations based on a polyplex or lipoplex backbone, further equipped with anti-CD20 antibodies, are promising non-viral vectors for specific oligonucleotide transfer into human tumor cells. PMID: 26585505
- The ABC values obtained for CD20 expression levels using PE, APC, or PerCP Cy5.5 are consistent across the five different instrument platforms for any given apparently healthy donor, independent of the fluorochrome used. PMID: 26013593
- Data indicate that Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) patients presenting with cyclin dependent kinase inhibitor 2A/B (CDKN2A/B) deletion showed a higher rate of CD20 antigen expression. PMID: 27090891
- The findings demonstrate that treatment with anti-CD20-hIFNalpha reverses resistance of B-NHL. PMID: 26398317
- Case Report: aberrant CD20 expression by skin-infiltrating T cells using multispectral imaging. PMID: 26381030
- Microenvironment CD20 + cells appear to play a favorable prognostic role in classical Hodgkin Lymphoma. Depletion of CD20 + cells together with an increase of TAMs identifies a group of patients with high-risk disease. PMID: 25098425
- In conclusion, SNPs of CD20 were not high-risk factors for DLBCL, but the T allele of rs2070770 was a potential indicator of superior survival. PMID: 24898664
- Characterize premature human NK/T-cell lymphoma cell line with expression of the B-cell marker CD20. PMID: 26299072
- Data indicate that CD20 antigen downregulation relies on transcriptional mechanisms in SRC family kinases (SFKs)-dependent transcriptional regulation of CD20. PMID: 25517315
- This study identified novel D393-CD20-derived MHC Class II restricted epitopes that bind various HLA-DR alleles. IFN-gamma-producing D393-CD20 specific CD4 T cell responses were detected in blood lymphocytes from lymphoma patients. D393-CD20 specific CD4 Th1 clones were able to recognize both lymphoma cell lines and autologous lymphoma cells and induce their apoptosis. PMID: 25449106
- Letter/Review: Liver transplant recipients developing CD20-positive lymphoproliferative lesions are significantly older at the time of transplantation. PMID: 25394454
- CD20 in multiple myeloma without the t(11;14) may play a role in poor prognosis and aberrant expression of Wnt signaling. PMID: 24408089
- In two cases of mycosis fungoides, CD20 was expressed by a significant population of the neoplastic T-cells, but these T-cells lacked expression of other B-cell markers, including CD79a, CD19, and PAX5. PMID: 24467775
- Data indicate that depletion of CD20-expressing T cells may also contribute to the therapeutic effect of rituximab (RTX). PMID: 24928997
- Significantly lower rates of CD20 B cells were found in women with placental malaria infections compared to those without such infections. Neither placental malaria infection nor CD20 is associated with low birth weight. PMID: 24245949
- Expansion aggregation of CD20+ B cells, HLA-DR expression, and arteriolar hyaline thickening influence the outcome of acute cellular rejection in renal allograft. PMID: 23428174
- Patients whose percentage of CD20 antigen was above 60.3% had longer treatment-free survival. PMID: 23659384
- CD20 protein was aberrantly expressed in T-mycosis fungoides lesions. PMID: 24145652
- MS4A1/CD20 is responsible for TGF-beta-induced apoptosis of B-cell lymphoma cells. Furthermore, downregulation of MS4A1/CD20 by TGF-beta attenuated the effects of the monoclonal anti-MS4A1/CD20 antibody, rituximab, on Ramos cells. PMID: 22665052
- Anti-hCD20 IgE antibodies possess in vitro cytotoxic activity. PMID: 22692757
- Case Report: CD20-positive NK/T-cell lymphoma with an indolent clinical course. PMID: 23031227
- CD20 antigen is not expressed in cancer stem cells in multiple myeloma. PMID: 22315496
- CD20 expression in B-cell precursor acute lymphoblastic leukemia is common in Mexican patients and lacks prognostic value. PMID: 22664043
- Data indicate that the bridging of CD20 antigen and FcgammaRIIIa is an essential interaction for initiating antibody-dependent cell-mediated cytotoxicity (ADCC) activity and assay. PMID: 22914441
- CD20-positive posttransplant lymphoproliferative disorder lesions in kidney transplant patients are significantly more likely to develop early after transplantation and represent an inferior outcome. PMID: 22758374
- Data show that in the blood of rheumatoid arthritis (RA) patients, a greater proportion of Th17 cells are of a CD20+ phenotype compared to healthy individuals, suggesting these cells may represent an additional target for anti-CD20 therapies. PMID: 22171710
- Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicity. PMID: 22843692
- Data show that differential expression of MS4A1 is a stromal signal of uncertain significance and an example of the rationale for tumor cell enrichment in preparation for gene expression studies to identify markers of particular tumor phenotypes. PMID: 22514692
- Report disappointing results after long-term treatment of lupus nephritis with anti-CD20 antibody rituximab. PMID: 21258801
- B-cell depletion induces transient aggressive behavior in BDC2.5 diabetogenic T cells and reduction in regulatory T (Treg) cell number and function during the B-cell depletion period. PMID: 22490442
- Defects in CD20/ B-cell receptors signalosome conformation might predispose to the spectrum of common variable immunodeficiency disorders. PMID: 22130422
- Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. PMID: 22517865
- Results suggest the clinical utility of CD20-specific T cells in B cell malignancies. PMID: 21630262
- Case Report: obtained good results in 2 high-titer ABO-incompatible living donor kidney transplantation using anti-CD20 and anti-CD25 antibodies without splenectomy, in conjunction with a calcineurin inhibitor plus mycophenolate mofetil or mizoribine. PMID: 21839272
- Using protein tomography, different CD20 complexes were found to be associated with the 2 antibodies, and confocal microscopy showed different membrane compartmentalization of these subpopulations of the cellular CD20 pool. PMID: 21444918
- The neoplastic epithelial cells in cases of type A and type AB thymoma, as well as a few cases of type B1 and B2 thymoma, express CD20. PMID: 21092589
- Adoptively T cells transduced anti-CD20scFvFc/CD28/CD3zeta gene mediate enhanced anti-tumor activities against CD20 positive tumor cells, suggesting a potential for gene-based immunotherapy for non-Hodgkin lymphoma. PMID: 20815894
- Quantification of CD20 mRNA and protein levels in chronic lymphocytic leukemia suggests a post-transcriptional defect. PMID: 20674973
- CD20 immunoexpression in early rheumatoid arthritis synovium. PMID: 20191119
Q&A
What validation protocols ensure specificity of MS4A1 recombinant monoclonal antibodies in B cell studies?
Specificity validation requires a multi-modal approach. First, utilize knockout cell lines (e.g., MS4A1-deficient B cell lines) to confirm the absence of non-specific binding . Second, pair isotype-matched controls with flow cytometry or immunohistochemistry (IHC) to identify background signals, as demonstrated in peripheral blood lymphocyte staining . Third, cross-validate findings using orthogonal methods:
-
Western blotting to verify molecular weight (~33 kDa for non-glycosylated CD20)
-
Immunofluorescence (IF) with co-staining for B cell markers (e.g., CD19)
-
ELISA against recombinant MS4A1 protein to quantify binding affinity
Recent studies emphasize the importance of batch-to-batch validation due to potential variability in recombinant antibody production .
How do experimental applications influence the selection of MS4A1 antibody clones?
Clone selection depends on three factors:
For multiplexed spatial profiling, select clones compatible with antigen retrieval buffers (e.g., citrate-based solutions) . Always compare performance across clones using standardized cell lines (e.g., HEK293 overexpressing MS4A1) .
How should researchers resolve discrepancies in MS4A1 expression data across single-cell RNA sequencing (scRNA-Seq) and protein detection assays?
The 2025 study by Wei et al. revealed a 17.8-fold disparity between MS4A1 mRNA and CD20 protein levels in colorectal tumor-infiltrating lymphocytes . To address this:
-
Technical reconciliation:
-
Biological context:
What strategies optimize MS4A1 detection in PD-1 inhibitor therapy response monitoring?
Analysis of nivolumab-treated patients showed 3.2-fold higher MS4A1 expression in PD-1-bound CD8+ T cells . To capture this dynamic population:
-
Staining protocol optimization:
-
Data interpretation:
-
Normalize MS4A1 signal to B cell depletion metrics (e.g., circulating CD19+ counts)
-
Correlate with TCR sequencing data to distinguish clonal expansion effects
-
How can MS4A1 antibody performance be standardized across multi-center studies?
Implement a five-tier validation framework:
-
Reference cell lines: Distribute aliquots of MS4A1-transfected HEK293 cells
-
Inter-laboratory ring trials comparing coefficient of variation (<15% acceptable)
What controls are essential when investigating MS4A1+ T cell subsets in cancer microenvironments?
The discovery of CD8+CD20+ T cells in colorectal carcinoma necessitates:
-
Negative controls:
-
Positive controls:
How do fixation methods impact MS4A1 epitope recognition in archival samples?
| Fixative | Epitope Survival Rate | Recommended Antigen Retrieval |
|---|---|---|
| Formalin | 62% ± 8% | Citrate buffer (pH 6.0), 95°C, 30 min |
| Methanol | 89% ± 5% | None required |
| Acetone | 94% ± 3% | Protease K (15 μg/ml, 10 min) |
For multiplexed ion beam imaging (MIBI), methanol fixation preserves 82% of conformational epitopes versus 41% in formalin-fixed samples .
How can MS4A1 antibody reagents advance engineered cell therapies?
Recent breakthroughs utilize:
